White Papers

White PapersLinks

Assessing RA-patient Autoantibody Response to Citrullinated Immunome Proteins

View Paper

KREX Protein Arrays for Rapid Screening of Vaccine Candidates

View Paper

Autoantibody Discovery using a Novel Microarray of Functional Proteins

View Paper

Rapid Determination of the Effect of Genetic Mutations on Protein Function

View Paper

Fully Functional Protein Microarray for Predictive Toxicology Studies

View Paper

Exploring Diverse Protein Interactions using the Sengenics Protein Array

View Paper

FEATURED PRODUCTS

High-throughput autoantibody profiling against 1600+ proteins

Quantification of autoantibodies to 200+ clinically relevant CT antigens

Simultaneous screening of 100+
wild-type and mutant p53

Multi-antigen, multi-domain
COVID-19 antibody test

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389